-
公开(公告)号:US20240317733A1
公开(公告)日:2024-09-26
申请号:US18449326
申请日:2023-08-14
发明人: Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号: C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
CPC分类号: C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubral pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula
wherein each symbol is as defined in the present specification, or a salt thereof.-
公开(公告)号:US12012397B2
公开(公告)日:2024-06-18
申请号:US17967599
申请日:2022-10-17
申请人: NodThera Limited
发明人: David Harrison , Alan Paul Watt , Mark G. Bock
IPC分类号: C07D403/12 , C07D231/38 , C07D237/20 , C07D239/42 , C07D249/04 , C07D249/14 , C07D261/14 , C07D277/52 , C07D285/135 , C07D307/66 , C07D401/12 , C07D405/12 , C07D471/08
CPC分类号: C07D403/12 , C07D231/38 , C07D237/20 , C07D239/42 , C07D249/04 , C07D249/14 , C07D261/14 , C07D277/52 , C07D285/135 , C07D307/66 , C07D401/12 , C07D405/12 , C07D471/08 , C07B2200/05
摘要: The present disclosure relates to compounds of Formula (I):
and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.-
公开(公告)号:US20240043395A1
公开(公告)日:2024-02-08
申请号:US18027005
申请日:2021-09-24
IPC分类号: C07D285/135 , C07D277/46 , C07D277/56 , C07D295/112 , C07D263/48 , C07D277/24 , C07D213/75 , C07D211/26 , C07D295/16 , C07D207/09 , C07D205/04 , C07D237/20 , C07D231/12 , C07D417/14 , C07D417/04 , C07F9/6558 , C07D213/74 , C07D295/135 , C07D265/30 , C07D279/12 , C07C235/62 , C07C243/38 , C07D211/96 , C07D417/12 , C07D417/10 , C07D285/08 , C07D241/04 , C07D221/20 , C07D401/04
CPC分类号: C07D285/135 , C07D401/04 , C07D277/56 , C07D295/112 , C07D263/48 , C07D277/24 , C07D213/75 , C07D211/26 , C07D295/16 , C07D207/09 , C07D205/04 , C07D237/20 , C07D231/12 , C07D417/14 , C07D417/04 , C07F9/65583 , C07D213/74 , C07D295/135 , C07D265/30 , C07D279/12 , C07C235/62 , C07C243/38 , C07D211/96 , C07D417/12 , C07D417/10 , C07D285/08 , C07D241/04 , C07D221/20 , C07D277/46
摘要: The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.
-
公开(公告)号:US20230295147A1
公开(公告)日:2023-09-21
申请号:US18166689
申请日:2023-02-09
申请人: Ikena Oncology, Inc.
IPC分类号: C07D417/04 , A61P1/00 , A61P29/00 , C07D235/00 , C07D249/14 , C07D263/48 , C07D271/07 , C07D271/113 , C07D277/42 , C07D277/48 , C07D285/135 , C07D333/36 , C07D417/12
CPC分类号: C07D417/04 , A61P1/00 , A61P29/00 , C07D235/00 , C07D249/14 , C07D263/48 , C07D271/07 , C07D271/113 , C07D277/42 , C07D277/48 , C07D285/135 , C07D333/36 , C07D417/12
摘要: The present invention provides AHR agonists, compositions thereof, and methods of using the same.
-
公开(公告)号:US11634391B2
公开(公告)日:2023-04-25
申请号:US17272268
申请日:2019-08-30
申请人: UCL BUSINESS LTD
发明人: Paul Vincent Fish , William Mahy , Nicky John Willis , Hannah Woodward , Benjamin N Atkinson , Elliott D Bayle , James Sipthorp , Edith Yvonne Jones , Yuguang Zhao , Luca Vecchia , Reinis Reinholds Ruza
IPC分类号: C07D249/06 , C07D249/12 , C07D231/12 , C07D207/34 , C07D213/16 , C07D213/64 , C07D231/20 , C07D233/56 , C07D233/64 , C07D237/14 , C07D239/34 , C07D239/36 , C07D249/08 , C07D257/04 , C07D261/08 , C07D263/32 , C07D271/06 , C07D271/07 , C07D271/113 , C07D285/06 , C07D285/135 , C07D401/04 , C07D403/04 , C07D403/10 , C07D405/04 , C07D413/04 , C07D413/10
摘要: A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)
-
公开(公告)号:US20230037883A1
公开(公告)日:2023-02-09
申请号:US17754669
申请日:2020-09-30
发明人: Bing SUN , Huibin YANG , Hongjuan MA , Junwu YING , Dongliang CUI , Bo QIN , Shuang LIANG , Gang WANG , Zhengmao LU , Fan ZHANG , Lin CHEN , Heying PEI , Yan CHENG , Mingxin WANG , Bin LI
IPC分类号: C07D257/06 , A01N43/713 , C07D405/12 , C07D401/12 , C07D403/12 , C07D413/12 , A01N43/80 , A01N43/82 , C07D271/113 , C07D285/135 , C07D249/14 , C07D271/04 , C07D413/14 , C07D401/14 , C07D417/12 , A01P13/00
摘要: An alkene-containing amide compound of formula (I) and agriculturally acceptable salts thereof can be used as herbicides.
-
公开(公告)号:US20220213047A1
公开(公告)日:2022-07-07
申请号:US17552413
申请日:2021-12-16
发明人: Daniel P. Flaherty , Mohamed Seleem
IPC分类号: C07D285/135 , A61P31/04 , C07D417/12
摘要: The invention described generally relates to novel therapeutic compounds, and in particular to carbonic anhydrase inhibitors as an antibiotic against Neisseria gonorrhea bacteria and methods for treating those sexually transmitted infection diseases in mammals using the described carbonic anhydrase inhibitors having a formula (I), or a pharmaceutical formulation thereof, alone or together with one or more other antibiotics.
-
公开(公告)号:US11339152B2
公开(公告)日:2022-05-24
申请号:US16497040
申请日:2018-04-03
发明人: Ulrich Heiser , Torsten Hoffmann , Ingeborg Lues , Antje Meyer
IPC分类号: C07D417/12 , C07D235/08 , C07D249/14 , C07D277/40 , C07D285/135 , C07D401/04 , C07D401/12 , C07D403/12 , C07D417/04 , A61K45/06
摘要: The invention relates to a compound of formula (I): A-B-D-E (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein: A is selected from monocyclic and bicyclic heteroaryl, which may independently substituted by alkyl or amino; B is selected from alkyl, heteroalkyl, alkyl-amino, aryl, heteroaryl, cycloalkyl, heterocyclyl and alkylene, wherein said groups may independently be substituted by alkyl; D is selected from aryl-amino, heteroaryl-amino, cycloalkyl-amino, heterocyclyl, heterocyclyl-amino, urea, thioamide, thiourea, sulfonamide, sulfoximine and sulfamoyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups may independently be substituted; and E is selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups may independently be substituted. The compounds of formula (I) are inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
-
公开(公告)号:US11230524B2
公开(公告)日:2022-01-25
申请号:US15999268
申请日:2018-08-17
申请人: STANDARD LLC
发明人: Junhu Zhang
IPC分类号: C07C237/20 , C07D213/30 , C07D417/04 , C07D263/48 , C07C233/44 , C07C259/06 , C07C323/36 , C07D215/38 , C07D277/82 , C07D305/08 , C07D285/135 , C07D271/113 , C07D213/56 , C07D209/14 , C07D295/135 , C07D213/74 , C07D401/04
摘要: The present disclosure provides novel compounds capable of functioning as Myocyte Enhancer Factor 2 (MEF2) modulators, as well as compositions, pharmaceutical formulations, methods of synthesis and kits.
-
公开(公告)号:US20210221778A1
公开(公告)日:2021-07-22
申请号:US16501272
申请日:2017-09-12
申请人: Nuria Vilaboa , Richard W. Voellmy
发明人: Nuria Vilaboa , Richard W. Voellmy
IPC分类号: C07D277/46 , C07D277/82 , C07D333/36 , C07D417/04 , C07D417/12 , C07D277/56 , C07D417/14 , C07D263/48 , C07D261/14 , C07D231/40 , C07D285/135 , C07D213/75 , C07D215/42 , A61P35/00
摘要: The present disclosure relates to a class of mammalian heat shock factor (HSF) inhibitors, to pharmaceutical compositions comprising these inhibitors as well as to methods for using the inhibitors. The inhibitors inhibit stress-induced expression from heat shock gene promoters. Furthermore, the inhibitors are cytotoxic to a variety of human cancer cells types.
-
-
-
-
-
-
-
-
-